← Back
Data updated: Jun 28, 2026
HORIZON THERAP US
Specialty Pharmaceuticals
HORIZON THERAP US is a specialty pharmaceutical company with 2 FDA-approved products.
1996
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
HORIZON THERAP US's Key Drugs
HORIZON THERAP US's core commercial portfolio centers on RAVICTI — its most strategically important drugs approved in the last 15 years.
HORIZON THERAP US's Recent FDA Approvals
New NDA/BLA approvals for HORIZON THERAP US over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
HORIZON THERAP US's Therapeutic Areas
Disease areas where HORIZON THERAP US has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
HORIZON THERAP US Pipeline Snapshot
Active clinical trials for HORIZON THERAP US across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • RAVICTI leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1996-04-30
- Latest
- 2022-07-29
- Applications
- 3